Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Effect of metoprolol versus carvedilol on outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy).

Ruwald MH, Ruwald AC, Jons C, Alexis J, McNitt S, Zareba W, Moss AJ.

J Am Coll Cardiol. 2013 Apr 9;61(14):1518-26. doi: 10.1016/j.jacc.2013.01.020.

2.

Cardiac resynchronization therapy in patients with minimal heart failure: a systematic review and meta-analysis.

Adabag S, Roukoz H, Anand IS, Moss AJ.

J Am Coll Cardiol. 2011 Aug 23;58(9):935-41. doi: 10.1016/j.jacc.2011.05.022. Review.

3.

Opportunity to increase life span in narrow QRS cardiac resynchronization therapy recipients by deactivating ventricular pacing: evidence from randomized controlled trials.

Sohaib SM, Finegold JA, Nijjer SS, Hossain R, Linde C, Levy WC, Sutton R, Kanagaratnam P, Francis DP, Whinnett ZI.

JACC Heart Fail. 2015 Apr;3(4):327-36. doi: 10.1016/j.jchf.2014.11.007. Epub 2015 Mar 11. Review.

PMID:
25770400
4.

Effectiveness of implantable cardioverter defibrillators and cardiac resynchronization therapy in heart failure.

Freeman JV, Masoudi FA.

Heart Fail Clin. 2013 Jan;9(1):59-77. doi: 10.1016/j.hfc.2012.09.006. Epub 2012 Oct 13. Review.

PMID:
23168318
5.

Cardiac resynchronization therapy in patients with mild heart failure: a systematic review and meta-analysis.

Santangeli P, Di Biase L, Pelargonio G, Dello Russo A, Casella M, Bartoletti S, Burkhardt JD, Mohanty P, Santarelli P, Natale A.

J Interv Card Electrophysiol. 2011 Nov;32(2):125-35. doi: 10.1007/s10840-011-9584-y. Epub 2011 May 19. Review.

PMID:
21594629
6.

Importance of Implantable Cardioverter-Defibrillator Back-Up in Cardiac Resynchronization Therapy Recipients: A Systematic Review and Meta-Analysis.

Barra S, ProvidĂȘncia R, Tang A, Heck P, Virdee M, Agarwal S.

J Am Heart Assoc. 2015 Nov 6;4(11). pii: e002539. doi: 10.1161/JAHA.115.002539. Review.

7.

The efficacy and safety of cardiac resynchronization therapy combined with implantable cardioverter defibrillator for heart failure: a meta-analysis of 5674 patients.

Chen S, Ling Z, Kiuchi MG, Yin Y, Krucoff MW.

Europace. 2013 Jul;15(7):992-1001. doi: 10.1093/europace/eus419. Epub 2013 Feb 17. Review.

PMID:
23419662
8.

Lessons learned from the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT).

Kutyifa V, Goldenberg I, Moss AJ.

Trends Cardiovasc Med. 2016 Feb;26(2):137-46. doi: 10.1016/j.tcm.2015.04.013. Epub 2015 Apr 30. Review.

PMID:
26051208
9.

An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure.

Cleland JG, Abraham WT, Linde C, Gold MR, Young JB, Claude Daubert J, Sherfesee L, Wells GA, Tang AS.

Eur Heart J. 2013 Dec;34(46):3547-56. doi: 10.1093/eurheartj/eht290. Epub 2013 Jul 29. Review.

10.

Cardiac-resynchronization therapy in patients with systolic heart failure and QRS interval ≀130 ms: insights from a meta-analysis.

Shah RM, Patel D, Molnar J, Ellenbogen KA, Koneru JN.

Europace. 2015 Feb;17(2):267-73. doi: 10.1093/europace/euu214. Epub 2014 Aug 27. Review.

PMID:
25164431
11.

20 years of cardiac resynchronization therapy.

Leyva F, Nisam S, Auricchio A.

J Am Coll Cardiol. 2014 Sep 9;64(10):1047-58. doi: 10.1016/j.jacc.2014.06.1178. Review.

12.

Cardiac resynchronization therapy and QRS duration: systematic review, meta-analysis, and meta-regression.

Kang SH, Oh IY, Kang DY, Cha MJ, Cho Y, Choi EK, Hahn S, Oh S.

J Korean Med Sci. 2015 Jan;30(1):24-33. doi: 10.3346/jkms.2015.30.1.24. Epub 2014 Dec 23. Review.

13.

More favorable response to cardiac resynchronization therapy in women than in men.

Cheng YJ, Zhang J, Li WJ, Lin XX, Zeng WT, Tang K, Tang AL, He JG, Xu Q, Mei MY, Zheng DD, Dong YG, Ma H, Wu SH.

Circ Arrhythm Electrophysiol. 2014 Oct;7(5):807-15. doi: 10.1161/CIRCEP.113.001786. Epub 2014 Aug 21. Review.

14.

Baseline Functional Class and Therapeutic Efficacy of Common Heart Failure Interventions: A Systematic Review and Meta-analysis.

Miller RJ, Howlett JG, Exner DV, Campbell PM, Grant AD, Wilton SB.

Can J Cardiol. 2015 Jun;31(6):792-9. doi: 10.1016/j.cjca.2014.12.031. Epub 2015 Jan 7. Review.

PMID:
26022990
16.

Meta-analysis of the effects of carvedilol versus metoprolol on all-cause mortality and hospitalizations in patients with heart failure.

Briasoulis A, Palla M, Afonso L.

Am J Cardiol. 2015 Apr 15;115(8):1111-5. doi: 10.1016/j.amjcard.2015.01.545. Epub 2015 Jan 31. Review.

PMID:
25708861
17.

Why the Authors Use Cardiac Resynchronization Therapy with Defibrillators.

Sze E, Daubert JP.

Card Electrophysiol Clin. 2015 Dec;7(4):695-707. doi: 10.1016/j.ccep.2015.08.017. Review.

PMID:
26596812
18.

Cardiac resynchronization therapy: state of the art 2013.

Yu CM, Hayes DL.

Eur Heart J. 2013 May;34(19):1396-403. doi: 10.1093/eurheartj/ehs454. Epub 2013 Jan 25. Review.

PMID:
23355652
19.

Individual patient data network meta-analysis of mortality effects of implantable cardiac devices.

Woods B, Hawkins N, Mealing S, Sutton A, Abraham WT, Beshai JF, Klein H, Sculpher M, Plummer CJ, Cowie MR.

Heart. 2015 Nov;101(22):1800-6. doi: 10.1136/heartjnl-2015-307634. Epub 2015 Aug 12. Review.

20.

BLOCK HF: how far does it extend indications for cardiac resynchronization therapy?

Boriani G, Ziacchi M, Diemberger I, Biffi M, Martignani C, Leyva F.

J Cardiovasc Med (Hagerstown). 2016 Apr;17(4):306-8. doi: 10.2459/JCM.0000000000000147. Review.

PMID:
25405947

Supplemental Content

Support Center